SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

brelovitug

MIRM·Mirum Pharmaceuticals, Inc.
BULLISH
Drug Impact Rating6/10
Trial phase
Phase 3 (completed)
Time to market
Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
Why 6/10
The next hard, dated catalyst is the planned BLA submission for brelovitug in HDV in H1 2027 (by June 30, 2027). This is a major regulatory milestone for a late-stage asset that is a significant value driver for Mirum, but Mirum also has substantial approved-product revenue (~$715-720M in 2026 net product sales) and a broader pipeline, so the company is not a single-asset binary.
Actionable Insight BULLISH

Brelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

Price Chart

Loading chart...

Executive Summary

Brelovitug is Mirum Pharmaceuticals' investigational monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver infection. The drug has now succeeded in two pivotal Phase 3 trials (AZURE-1 in September 2026 and AZURE-4 on November 10, 2026), both meeting their primary endpoints of combined virologic response and ALT normalization. Mirum acquired brelovitug through its January 2026 acquisition of Bluejay Therapeutics for up to $820M. The drug has FDA Breakthrough Therapy and Orphan Drug designations, and Mirum plans to submit a BLA in H1 2027. The main competition is Gilead's Hepcludex (bulevirtide), which received FDA accelerated approval in May 2026 as the first approved HDV treatment in the US. Mirum is already a profitable commercial-stage company with ~$715-720M in 2026 net product sales from its approved liver disease drugs.

How It Works

A fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), a protein on the surface of the hepatitis B virus that the hepatitis delta virus (HDV) needs to infect liver cells. By binding HBsAg, brelovitug neutralizes the virus and blocks HDV from entering and replicating in liver cells.

Trial Status

Two pivotal Phase 3 trials have both met their primary endpoints. AZURE-1 (Phase 2b/3) met its primary endpoint in September 2026, showing combined virologic response and ALT normalization at Week 24. AZURE-4 (Phase 3) met its primary endpoint on November 10, 2026, with 59% of patients receiving 300 mg once weekly achieving the combined endpoint at Week 24. Long-term data showed 100% virologic response and 100% ALT normalization in patients with cirrhosis following up to 108 weeks of treatment. A third Phase 3 trial, AZURE-2, comparing brelovitug head-to-head against Gilead's Hepcludex (bulevirtide, is ongoing.

The Two-Sided Case

▲ Bull Case1
Brelovitug has now succeeded in two pivotal Phase 3 trials (AZURE-1 and AZURE-4), de-risking its regulatory path significantly. The drug has FDA Breakthrough Therapy and Orphan Drug designations, which could accelerate review. Long-term data showing 100% response in cirrhosis patients is a strong differentiator. Mirum already has a commercial infrastructure and ~$715-720M in annual product sales from approved drugs (Livmarli, bile acid medicines), meaning it can fund the launch without dilutive financing. Analyst consensus is Strong Buy with a mean price target of $155, implying ~66% upside from the November 10 close of $94.42.
▼ Bear Case1
Gilead's Hepcludex (bulevirtide) was approved by the FDA in May 2026 as the first and only approved treatment for chronic HDV, giving it first-mover advantage and established physician familiarity. The AZURE-2 trial is a head-to-head comparison against Hepcludex, and brelovitug's commercial differentiation versus Hepcludex is unproven. HDV is a very small market (estimated ~100,000 patients in the US), limiting peak sales potential. BLA submission is still months away (H1 2027), and the stock already reflects significant gains (up ~13% on orphan drug news alone). Insider sales by CEO Christopher Peetz sold $1.8M of stock on November 4, 2026 at $90/share.

Upcoming Catalysts

  • BLA submission to FDA planned for H1 2027
  • AZURE-2 head-to-head Phase 3 data vs Hepcludex (bulevirtide) - timing undisclosed
  • Potential FDA Accelerated Approval pathway decision

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Mirum Pharmaceuticals, Inc. 8-K MIRM ·Originating report

Sources · 9

Hover a chip for the title
1 fiercebiotech.com2 aol.com3 marketscreener.com4 msn.com5 rttnews.com6 fiercebiotech.com7 biospace.com8 sec.gov9 clinicaladvisor.com